A 2021 research paper authored by Jeffrey Cummings, MD, ScD, and colleagues estimated the cumulative expenditures to fund Alzheimer disease (AD) clinical trials over the past quarter-century and highlighted the numerous failed attempts that continue to plague the field. Overall, excluding the recent approval of aducanumab (Aduhelm; Biogen), there have only been 5 drugs—all for symptomatic treatment only—that have achieved FDA approval for AD since 1995. An estimated $42.5 billion in private expenditures has been sunk into AD clinical trials since then, with phase 3 representing the highest stage for costs of research and development ($24.1B).

Expert clinicians offer their insight on costs of Alzheimer drug development, a new agent for generalized myasthenia gravis, migraine in the emergency department, educational sleep medicine “boot camps”, AES 2021, and more.

The director of the Chambers-Grundy Center for Transformative Neuroscience at the University of Nevada–Las Vegas detailed the steps necessary to lower wasted costs from Alzheimer disease drug development and improve regulatory success.

When I realized how under fueled I was, I knew I had to rethink my eating habits.

This year has been a major year in the field of Alzheimer disease (AD), with several promising therapies moving forward and the first FDA approval in almost 2 decades.

Air Force veteran Ally Schroeder, 27, will graduate in May from UNLV with a bachelor’s degree in nutrition sciences. She has been paying for her tuition and housing through the G.I. Bill, which has provided money toward schooling or job training to service members since the 1940s.

It’s called the Chambers-Grundy Center for Transformative Neuroscience at UNLV, and the adjective in the name says it all.

The director of the Chambers-Grundy Center for Transformative Neuroscience at the University of Nevada–Las Vegas discussed new data that highlights wasted expenditures from Alzheimer trials and the importance of understanding their impacts.

The pandemic put a lot of people out of work, which meant a lot of people did not know where their next meal would come from. Now that more people are back to work, inflation means food is costing a lot.

Pharmacological studies have attempted and failed for past decades to generate medicines that might halt the course of the illness. Now, experts claim to have reached a tipping point in Alzheimer's development.

The cause of Alzheimer’s was supposedly simple.

Alzheimer’s treatments seemed unlikely just a few months ago.